Overview

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
Phase:
Phase 4
Details
Lead Sponsor:
John H. Stroger Hospital
Collaborator:
Cook County Hospital
Treatments:
Enoxaparin
Rivaroxaban
Warfarin